Head-To-Head Contrast: Clarus Therapeutics (OTCMKTS:CRXTQ) vs. Prime Medicine (NYSE:PRME)

Prime Medicine (NYSE:PRME) and Clarus Therapeutics (OTCMKTS:CRXTQ) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, analyst recommendations and valuation.

Valuation and Earnings

This table compares Prime Medicine and Clarus Therapeutics’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	N/A	N/A	-$198.13 million	($2.17)	-2.60
Clarus Therapeutics	$13.96 million	N/A	-$40.62 million	N/A	N/A

Clarus Therapeutics has higher revenue and earnings than Prime Medicine.

Profitability

This table compares Prime Medicine and Clarus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prime Medicine	N/A	-94.21%	-74.52%
Clarus Therapeutics	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for Prime Medicine and Clarus Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	0	2	10	0	2.83
Clarus Therapeutics	0	0	0	0	N/A

Prime Medicine currently has a consensus target price of $15.09, suggesting a potential upside of 167.10%. Given Prime Medicine’s higher possible upside, equities research analysts clearly believe Prime Medicine is more favorable than Clarus Therapeutics.

Institutional and Insider Ownership

70.4% of Prime Medicine shares are owned by institutional investors. 24.3% of Prime Medicine shares are owned by insiders. Comparatively, 5.3% of Clarus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

About Prime Medicine

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

About Clarus Therapeutics

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.